Zollinger‑Ellison syndrome – associated with NF1 - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑secreting tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to produce large amounts of gastric acid, leading to severe peptic ulcer disease, chronic diarrhea, and malabsorption.

When ZES occurs in a person with Neurofibromatosis type 1 (NF‑1), the condition is considered part of the broader spectrum of neuro‑endocrine tumor (NET) manifestations seen in this genetic disorder. NF‑1 is an autosomal‑dominant condition caused by mutations in the NF1 tumor‑suppressor gene, affecting skin, nerves, and various internal organs.

Who it affects

• Overall incidence of ZES is about 0.5–2 cases per million per year worldwide (Mayo Clinic, 2023).
• Approximately 5–10 % of patients with ZES have an underlying genetic syndrome; of these, 2–4 % are linked to NF‑1.
• Both sexes are equally affected, and the median age at diagnosis is 45 years, but patients with NF‑1 may present earlier, often in their 30s.

Symptoms

Because excess gastric acid affects many parts of the gastrointestinal (GI) tract, ZES produces a broad symptom profile. In NF‑1 patients the presentation can be atypical due to co‑existing GI neuro‑fibromas.

Gastro‑intestinal symptoms

• Abdominal pain – crampy, often worse after meals.
• Refractory peptic ulcers – ulcers that persist despite standard therapy; can occur in the duodenum, jejunum, or even the distal small bowel.
• Frequent heartburn or gastro‑esophageal reflux disease (GERD).
• Chronic watery diarrhea – up to 5–10 stools per day; caused by acid‑induced damage to the intestinal mucosa and rapid transit.
• Steatorrhea (fatty stools) – malabsorption of fats leading to foul‑smelling stools.
• Nausea and vomiting – especially after large meals.

Systemic symptoms

• Unexplained weight loss – due to malabsorption and chronic diarrhea.
• Fatigue – secondary to anemia from chronic GI bleeding.
• Osteopenia/osteoporosis – chronic acid load can impair calcium absorption.

Signs pointing to NF‑1 co‑existence

• Café‑au‑lait macules, neurofibromas, or Lisch nodules on eye exam.
• History of other NF‑1–related tumors (e.g., pheochromocytoma, gastrointestinal stromal tumors).

Causes and Risk Factors

ZES is primarily a neuro‑endocrine tumor (NET) disorder. The underlying mechanisms differ between sporadic cases and those linked to NF‑1.

Pathophysiology

1. Gastrinoma formation – Mutations in the MEN1 gene (in MEN‑1 syndrome) or loss of function of the NF1 tumor suppressor gene lead to uncontrolled proliferation of gastrin‑producing cells.
2. Hypergastrinemia – Tumors secrete gastrin at levels 10‑fold higher than normal, stimulating parietal cells.
3. Acid hypersecretion – Gastric acid output can exceed 30 mEq/hour (normal < 5 mEq/h), eroding the mucosal barrier.
4. Ulceration and malabsorption – Acid damages the duodenal and jejunal lining, causing ulcers and impairing nutrient absorption.

Risk factors specific to NF‑1

• Germline NF1 mutation – present in >95 % of individuals with NF‑1.
• Family history of NF‑1 – Increases likelihood of neuro‑endocrine manifestations.
• Previous GI neuro‑fibromas – May reflect a predisposition to GI NETs.

Other risk factors for ZES (non‑NF‑1)

• MEN‑1 syndrome (mutations in MEN1 gene).
• Familial isolated gastrinoma (rare).
• Chronic H. pylori infection – can mimic ulcer disease but does not cause gastrinoma.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential, especially in patients with NF‑1 who have refractory GI complaints.

Initial laboratory tests

• Fasting serum gastrin – Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive. Values 2–3× upper limit with a gastric pH < 2 are also diagnostic (NIH, 2022).
• Secretin stimulation test – Intravenous secretin paradoxically raises gastrin > 120 pg/mL in ZES; used when basal gastrin is equivocal.
• Serum chromogranin A – A general NET marker; elevated in > 80 % of gastrinomas.
• Complete blood count (CBC) – To assess anemia from occult bleeding.

Imaging studies

1. Endoscopic ultrasound (EUS) – Highly sensitive for detecting pancreatic gastrinomas (≈ 80 % detection).
2. Multiphasic contrast‑enhanced CT or MRI – Identifies primary tumors and liver metastases.
3. Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – Gold standard for staging neuro‑endocrine tumors; detects lesions as small as 5 mm.
4. Selective arterial secretagogue injection (SASI) test – Rarely performed; helps localize gastrin-producing tissue when other imaging is negative.

Endoscopic evaluation

• Upper GI endoscopy (EGD) – Documents ulcer location, number, and severity; biopsies rule out H. pylori and malignancy.
• Capsule endoscopy or double‑balloon enteroscopy – Useful for detecting jejunal or ileal gastrinomas not seen on imaging.

Diagnostic criteria (summary)

• Fasting gastrin > 1000 pg/mL **or** fasting gastrin > 2× upper limit with gastric pH < 2, **plus** confirmation of a gastrinoma on imaging.
• Presence of NF‑1 does not alter the biochemical thresholds but raises suspicion for multiple small tumors.

Treatment Options

Treatment aims to control acid hypersecretion, remove or ablate the gastrinoma(s), and monitor for recurrence.

Medical management

• Proton pump inhibitors (PPIs) – High‑dose (e.g., omeprazole 60 mg daily or equivalent). PPIs are the cornerstone; they heal ulcers and control diarrhea in > 90 % of patients (Cleveland Clinic, 2023).
• H2‑receptor antagonists – Used when PPIs are contraindicated, but generally less effective.
• Octreotide or lanreotide (somatostatin analogues) – Inhibit gastrin release and may shrink tumor size; indicated for unresectable or metastatic disease.
• Interferon‑α – Occasionally used in refractory cases.

Surgical options

1. Enucleation – Preferred for solitary, small (< 2 cm) gastrinomas not involving major vessels.
2. Pancreaticoduodenectomy (Whipple procedure) – Considered for large or multiple duodenal gastrinomas.
3. Distal pancreatectomy or total pancreatectomy – Reserved for extensive pancreatic involvement.
4. Liver metastasectomy – Improves survival when hepatic disease is limited.

Locoregional therapies for metastases

• Radiofrequency ablation (RFA) or microwave ablation.
• Trans‑arterial embolization (TAE) or chemoembolization.
• Peptide receptor radionuclide therapy (PRRT) with 177Lu‑DOTATATE – Shows durable tumor control in NETs (NEJM, 2021).

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and alcohol – all aggravate ulcer formation.
• Eat small, frequent meals to reduce acid load.
• Supplement calcium and vitamin D if long‑term PPI use is required (to prevent osteoporosis).

Living with Zollinger‑Ellison syndrome – associated with NF1

Managing ZES in the context of NF‑1 demands a coordinated, multidisciplinary approach.

Daily management tips

• Medication adherence – Take PPIs exactly as prescribed; missing doses can precipitate ulcer flare‑ups.
• Monitor stool frequency – Record number, consistency, and any signs of blood.
• Regular nutritional assessment – Work with a dietitian to ensure adequate protein, calories, and fat absorption; consider medium‑chain triglyceride (MCT) oil if steatorrhea persists.
• Skin and nerve surveillance – Annual dermatologic exam for new neurofibromas; inform your gastroenterologist of any changes.
• Vaccinations – If undergoing chemotherapy or PRRT, stay up‑to‑date on pneumococcal, influenza, and COVID‑19 vaccines.
• Psychosocial support – Join NF‑1 or NET patient groups; coping with chronic illness can be stressful.

Follow‑up schedule

Visit Type	Frequency	Key Assessments
Gastroenterology	Every 3–6 months	Symptom review, PPI dose adjustment, CBC, serum gastrin
Endocrinology/Oncology	Every 6–12 months	Imaging (EUS/CT/MRI), chromogranin A, evaluation for metastasis
Dermatology/NF‑1 clinic	Annually or as needed	Neurofibroma count, skin cancer screening
Bone health (DEXA scan)	Every 2–3 years	Bone mineral density, calcium/vit D supplementation

Prevention

Because ZES is driven by genetic mutations, primary prevention is limited. However, risk reduction strategies are useful:

• Genetic counseling for individuals with NF‑1 or MEN‑1 to discuss family planning and early screening.
• Avoid H. pylori infection – Test and treat if positive; eradication lowers ulcer burden.
• Limit chronic gastric irritants – NSAIDs, smoking, and excessive alcohol consumption exacerbate acid injury.
• Early surveillance – For NF‑1 patients, baseline abdominal imaging at age 30‑35 can detect asymptomatic gastrinomas before complications develop.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated ulcer – Life‑threatening intra‑abdominal infection.
• Gastrointestinal bleeding – Chronic blood loss causing iron‑deficiency anemia.
• Benign or malignant gastric outlet obstruction – From scarring or tumor growth.
• Metastatic disease – Approximately 35–40 % of gastrinomas metastasize, most frequently to the liver and regional lymph nodes.
• Electrolyte disturbances – Chronic diarrhea leads to hypokalemia, metabolic alkalosis.
• Osteoporosis – Long‑term PPI use plus malabsorption can reduce bone density.
• Reduced quality of life – Persistent pain, malnutrition, and frequent medical visits.

When to Seek Emergency Care

Prompt treatment of these emergencies can be lifesaving and may prevent permanent organ damage.

---

References: Mayo Clinic. Zollinger‑Ellison Syndrome. 2023; NIH National Cancer Institute. Neuroendocrine Tumors. 2022; Cleveland Clinic. Gastrinomas and ZES. 2023; WHO Classification of Tumors of the Digestive System. 2022; NEJM. Peptide Receptor Radionuclide Therapy for NETs. 2021; CDC. Neurofibromatosis Type 1 Fact Sheet. 2024.

```